Education
About Us
Working with TipRanks
Follow Us
Vistagen Therapeutics Inc. (VTGN)
:VTGN
VTGN Stock Chart & Stats
$0.74
-$0.08(-2.56%)
At close: 4:00 PM EST
$0.74
-$0.08(-2.56%)
Day’s Range― - ―
52-Week Range$0.73 - $5.14
Previous CloseN/A
Volume188.19K
Average Volume (3M)3.26M
Market Cap
$34.01M
Enterprise Value$51.60M
Total Cash (Recent Filing)$77.17M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)―
Beta0.64
Next Earnings
Feb 12, 2026EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding39,495,453
10 Day Avg. Volume8,158,058
30 Day Avg. Volume3,258,660
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)1.09
Price to Sales (P/S)157.98
P/FCF Ratio-1.82
Enterprise Value/Market Cap1.52
Enterprise Value/Revenue71.57
Enterprise Value/Gross Profit93.48
Enterprise Value/Ebitda-0.81
Forecast
1Y Price Target
$0.97Price Target Upside31.08% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-1.7
Revenue Forecast (FY)$891.80K
Bulls Say, Bears Say
Bulls Say
Financial StabilityVistaGen exited the quarter with $77.2M in cash on the balance sheet, with cost-cutting measures being implemented to ensure a sufficient runway into 2027.
Market OpportunityThere is potential for fasedienol in this potential >30 million patient market in the U.S. alone.
Positive Trial ResultsVistaGen has an additional chance with the upcoming PALISADE-4 study to support a fasedienol NDA filing, following positive results from PALISADE-2.
Bears Say
Stock PerformanceVTGN shares are down 80% following the announcement of the P3 PALISADE-3 study results.
Trial FailuresThe P3 PALISADE-3 study of fasedienol for acute treatment of social anxiety disorder failed on the primary endpoint and there was no treatment difference vs. placebo for secondary endpoints.
Uncertainty In EfficacyThe Phase III PALISADE-3 study did not meet its primary endpoint compared to placebo, leading to uncertainty about fasedienol's efficacy for treating SAD.
VistaGen Therapeutics News
VTGN FAQ
What was Vistagen Therapeutics Inc.’s price range in the past 12 months?
Vistagen Therapeutics Inc. lowest stock price was $0.73 and its highest was $5.14 in the past 12 months.
What is Vistagen Therapeutics Inc.’s market cap?
Vistagen Therapeutics Inc.’s market cap is $34.01M.
When is Vistagen Therapeutics Inc.’s upcoming earnings report date?
Vistagen Therapeutics Inc.’s upcoming earnings report date is Feb 12, 2026 which is in 54 days.
How were Vistagen Therapeutics Inc.’s earnings last quarter?
Vistagen Therapeutics Inc. released its earnings results on Nov 13, 2025. The company reported -$0.54 earnings per share for the quarter, missing the consensus estimate of -$0.477 by -$0.063.
Is Vistagen Therapeutics Inc. overvalued?
According to Wall Street analysts Vistagen Therapeutics Inc.’s price is currently Undervalued.
Does Vistagen Therapeutics Inc. pay dividends?
Vistagen Therapeutics Inc. does not currently pay dividends.
What is Vistagen Therapeutics Inc.’s EPS estimate?
Vistagen Therapeutics Inc.’s EPS estimate is -0.49.
How many shares outstanding does Vistagen Therapeutics Inc. have?
Vistagen Therapeutics Inc. has 39,495,453 shares outstanding.
What happened to Vistagen Therapeutics Inc.’s price movement after its last earnings report?
Vistagen Therapeutics Inc. reported an EPS of -$0.54 in its last earnings report, missing expectations of -$0.477. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Vistagen Therapeutics Inc.?
Currently, no hedge funds are holding shares in VTGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VistaGen Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.97 (31.08% Upside)
$0.97 (31.08% Upside)
Blogger Sentiment
Bullish
VTGN Sentiment 70%
Sector Average 68%
Sector Average 68%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-68.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.04%
Trailing 12-Months
Company Description
Vistagen Therapeutics Inc.
VistaGen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with psychiatric and neurological disorders. The company leverages its proprietary drug development platform, including its human-derived stem cell technology, to create new treatments aimed at addressing unmet medical needs in mental health, particularly in major depressive disorder and anxiety-related conditions. VistaGen's core product candidates include AV-101, a novel oral treatment for major depressive disorder, and other pipeline candidates targeting various central nervous system (CNS) disorders.
VTGN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and a strong financial position, with strategic additions to the leadership team and a diverse pipeline poised for future growth. However, there were challenges in site management within clinical trials and uncertainty regarding FDA voucher eligibility.View all VTGN earnings summariesVTGN Stock 12 Month Forecast
Average Price Target
$0.97
▲(31.08% Upside)
Technical Analysis
MacroGenics
―
Ovid Therapeutics
―
Spero Therapeutics
―
Inhibikase Therapeutics
―
Surrozen
―
Ownership Overview
0.36% Insiders
4.48% Mutual Funds
36.26% Other Institutional Investors
54.29% Public Companies and Individual Investors